First-line chemotherapy in epithelial ovarian cancer

Clinical Obstetrics and Gynecology

Volumn 55, Issue 1, 2012, Pages 96-113

  Bookman, Michael A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

angiogenesis; carboplatin; chemotherapy; chemotherapy resistance; dose density; ovarian carcinoma

Indexed keywords

AFLIBERCEPT; ALISERTIB; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EC 145; EPIRUBICIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; GEMCITABINE; IRINOTECAN; IXABEPILONE; MONOCLONAL ANTIBODY IMC 1C11; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NINTEDANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLATINUM DERIVATIVE; SORAFENIB; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANGIOGENESIS; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG PENETRATION; DRUG SAFETY; DRUG SUBSTITUTION; EXCISION REPAIR; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; KIDNEY INJURY; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MITOSIS INDEX; MUCINOUS CARCINOMA; MUCOSA TOXICITY; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; OPTIMAL DRUG DOSE; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR DIFFERENTIATION; TUMOR VOLUME; VOMITING;

ADENOCARCINOMA, MUCINOUS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS AS TOPIC; CYSTADENOCARCINOMA, SEROUS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOPOTECAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857619192     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31824b45da     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
3. American Cancer Society, Cancer Facts & Figures 2010, Atlanta: American Cancer Society, 2010. Available at: http://www.cancer.org/Research/ CancerFactsFigures/CancerFactsFigures/cancer-factsfigures-2010-rev. Accessed October 19, 2010.
4. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol. 2010;28:18s(suppl; abstract LBA1).
5. Perren T, Swart AM, Pfisterer J, et al. ICON7: a phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). AnnOncol. 2010;21 (suppl 8): viii2-viii3(LBA4).
6. Möbus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007;25:4187-4193. (Pubitemid 47548557)
7. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34-43. (Pubitemid 43048949)
8. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955. (Pubitemid 26428219)
9. Spriggs DR, Brady MF, Vaccarello L, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:4466-4471. (Pubitemid 350013853)
10. Katsumata N, Yasuda M, Takahashi F, et al. Japanese Gynecologic Oncology GroupDose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.
11. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96: 1682-1691. (Pubitemid 39585637)
12. Bookman MA, Brady MF, McGuire W, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer InterGroup (GCIG). J Clin Oncol. 2009;27:1419-1425.
13. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol. 2006; 24:1127-1135. (Pubitemid 46638810)
14. Kristensen GB, Vergote I, Stuart G, et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/car boplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer. 2003;13 (suppl 2):172-177. (Pubitemid 38228761)
15. Bolis G, Scarfone G, Raspagliesi F, et al. Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage IIIIV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer. 2010;46:2905-2912.
16. Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin- topotecan and carboplatin- paclitaxel versus carboplatin-paclitaxel. J Natl Cancer Inst. 2010;102:1547-1556.
17. du Bois A, Herrstedt J,Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010;28:4162-4169.
18. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO- 2 randomized phase III trial. J Clin Oncol. 2011;29:3628-3635.
19. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in ancer. J Natl Cancer Inst. 2008;100: 1204-1214.
20. Guminski AD, Harnett PR, deFazio A. Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line-a potentialmechanism for paclitaxelmediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol. 2001;48:229-234. (Pubitemid 32758898)
21. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA. 2006;103:11154-11159. (Pubitemid 44156488)
22. Glinsky GV. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol. 2008; 26:2846-2853.
23. Bolis G, Danese S, Tateo S, et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer. 2006;16 (suppl 1):74-78.
24. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98: 1036-1045. (Pubitemid 44288151)
25. De Placido S, Scanbia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004;22:2635-2642. (Pubitemid 41103751)
26. PiccartMJ, Floquet A, Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum- based intravenous chemotherapy. Int J Gynecol Cancer. 2003;13 (suppl 2): 196-203. (Pubitemid 38228765)
27. Pecorelli S, Favalli G, Gadducci A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 Protocol. 1. J Clin Oncol. 2009;27:4642-4648.
28. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003; 21:2460-2465. (Pubitemid 46606325)
29. Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and highgrade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224. (Pubitemid 40170640)
30. Pohl G,Ho CL,KurmanRJ, et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res. 2005;65:1994-2000. (Pubitemid 40478629)
31. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene. 2005; 24:7443-7454. (Pubitemid 41637984)
32. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14:5198-5208.
33. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044. (Pubitemid 41095036)
34. Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627. (Pubitemid 47372600)
35. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:945-952.
36. Kristensen G, Perren T, Qian W, et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol. 2011;29(suppl; abstract LBA5006).
37. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: a randomized, doubleblinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011; 29(suppl; abstract LBA5007).
38. Gossage L, Madhusudan S. Current status of excision repair cross complementing- group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33:565-577. (Pubitemid 47355341)
39. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.